156 related articles for article (PubMed ID: 9973112)
1. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.
Murphy GP; Tjoa BA; Simmons SJ; Jarisch J; Bowes VA; Ragde H; Rogers M; Elgamal A; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Salgaller ML; Boynton AL
Prostate; 1999 Jan; 38(1):73-8. PubMed ID: 9973112
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.
Tjoa BA; Simmons SJ; Bowes VA; Ragde H; Rogers M; Elgamal A; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Salgaller ML; Boynton AL; Murphy GP
Prostate; 1998 Jun; 36(1):39-44. PubMed ID: 9650914
[TBL] [Abstract][Full Text] [Related]
3. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.
Murphy GP; Tjoa BA; Simmons SJ; Ragde H; Rogers M; Elgamal A; Kenny GM; Troychak MJ; Salgaller ML; Boynton AL
Prostate; 1999 Apr; 39(1):54-9. PubMed ID: 10221267
[TBL] [Abstract][Full Text] [Related]
4. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
Salgaller ML; Lodge PA; McLean JG; Tjoa BA; Loftus DJ; Ragde H; Kenny GM; Rogers M; Boynton AL; Murphy GP
Prostate; 1998 May; 35(2):144-51. PubMed ID: 9568678
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.
Murphy G; Tjoa B; Ragde H; Kenny G; Boynton A
Prostate; 1996 Dec; 29(6):371-80. PubMed ID: 8977634
[TBL] [Abstract][Full Text] [Related]
6. Follow-up evaluation of a phase II prostate cancer vaccine trial.
Tjoa BA; Simmons SJ; Elgamal A; Rogers M; Ragde H; Kenny GM; Troychak MJ; Boynton AL; Murphy GP
Prostate; 1999 Jul; 40(2):125-9. PubMed ID: 10386473
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
8. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
[TBL] [Abstract][Full Text] [Related]
10. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients.
Murphy GP; Tjoa BA; Simmons SJ; Rogers MK; Kenny GM; Jarisch J
Prostate; 2000 Apr; 43(1):59-62. PubMed ID: 10725866
[TBL] [Abstract][Full Text] [Related]
11. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based immunotherapy of prostate cancer.
Salgaller ML; Tjoa BA; Lodge PA; Ragde H; Kenny G; Boynton A; Murphy GP
Crit Rev Immunol; 1998; 18(1-2):109-19. PubMed ID: 9419453
[TBL] [Abstract][Full Text] [Related]
13. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides.
Tjoa BA; Erickson SJ; Bowes VA; Ragde H; Kenny GM; Cobb OE; Ireton RC; Troychak MJ; Boynton AL; Murphy GP
Prostate; 1997 Sep; 32(4):272-8. PubMed ID: 9288186
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.
Simmons SJ; Tjoa BA; Rogers M; Elgamal A; Kenny GM; Ragde H; Troychak MJ; Boynton AL; Murphy GP
Prostate; 1999 Jun; 39(4):291-7. PubMed ID: 10344219
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
16. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
17. Vaccine therapy for prostate cancer.
Tjoa BA; Elgamal AA; Murphy GP
Urol Clin North Am; 1999 May; 26(2):365-74, ix. PubMed ID: 10361559
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.
Prue RL; Vari F; Radford KJ; Tong H; Hardy MY; D'Rozario R; Waterhouse NJ; Rossetti T; Coleman R; Tracey C; Goossen H; Gounder V; Crosbie G; Hancock S; Diaz-Guilas S; Mainwaring P; Swindle P; Hart DN
J Immunother; 2015; 38(2):71-6. PubMed ID: 25658616
[TBL] [Abstract][Full Text] [Related]
20. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
Chudley L; McCann K; Mander A; Tjelle T; Campos-Perez J; Godeseth R; Creak A; Dobbyn J; Johnson B; Bass P; Heath C; Kerr P; Mathiesen I; Dearnaley D; Stevenson F; Ottensmeier C
Cancer Immunol Immunother; 2012 Nov; 61(11):2161-70. PubMed ID: 22729556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
